Bandaríkin - enska - NLM (National Library of Medicine)

bryant ranch prepack - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. - eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. - safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. eletriptan hydrobromide tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)]. - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pa

Bandaríkin - enska - NLM (National Library of Medicine)

rebel distributors corp - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan hydrobromide 40 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. relpax is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of relpax tablets have not been established for cluster headache, which is present in an older, predominantly male population. relpax tablets should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms, or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal's variant angina, or other significant underlying cardiovascular disease (see warnings). relpax tablets should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks (see warnings). relpax tablets should not be given to patients with peripheral

Bandaríkin - enska - NLM (National Library of Medicine)

roerig - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan 20 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. limitations of use: relpax is contraindicated in patients with: risk summary available human data on the use of relpax in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage. in animal studies, oral administration of eletriptan during pregnancy or throughout pregnancy and lactation was associated with developmental toxicity (decreased fetal and pup weights, increased incidences of fetal structural abnormalities, decreased pup viability) at clinically-relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the reported rate of major birth defects among deliveries to women with migraine ranged from 2.2% to 2.9% and the reported rate of miscarriage was 17%, which were similar to rates reported in women withou

Bandaríkin - enska - NLM (National Library of Medicine)

direct_rx - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. eletriptan hydrobromide tablets are contraindicated in patients with: ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)]. wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conducti

Bandaríkin - enska - NLM (National Library of Medicine)

physicians total care, inc. - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan 40 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. relpax is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of relpax tablets have not been established for cluster headache, which is present in an older, predominantly male population. relpax tablets should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms, or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal's variant angina, or other significant underlying cardiovascular disease (see warnings). relpax tablets should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks (see warnings). relpax tablets should not be given to patients with periphera

Bandaríkin - enska - NLM (National Library of Medicine)

stat rx usa llc - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan 40 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. relpax is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of relpax tablets have not been established for cluster headache, which is present in an older, predominantly male population. relpax tablets should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms, or findings consistent with ischemic heart disease, coronary artery vasospasm, including prinzmetal's variant angina, or other significant underlying cardiovascular disease (see warnings). relpax tablets should not be given to patients with cerebrovascular syndromes including (but not limited to) strokes of any type as well as transient ischemic attacks (see warnings). relpax tablets should not be given to patients with periphera

Bandaríkin - enska - NLM (National Library of Medicine)

u.s. pharmaceuticals - eletriptan hydrobromide (unii: m41w832ta3) (eletriptan - unii:22qoo9b8ki) - eletriptan 40 mg - relpax is indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with relpax, reconsider the diagnosis of migraine before relpax is administered to treat any subsequent attacks. - relpax is not intended for the prevention of migraine attacks. - safety and effectiveness of relpax have not been established for cluster headache. relpax is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1)]. - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)]. - history of stroke, transient ischemic attack (tia), or history or current evidence of hemipl

Malta - enska - Medicines Authority

pfizer hellas s.a. - eletriptan hydrobromide - film-coated tablet - eletriptan hydrobromide 20 milligram(s) - analgesics

Malta - enska - Medicines Authority

pfizer hellas s.a. - eletriptan hydrobromide - film-coated tablet - eletriptan hydrobromide 40 milligram(s) - analgesics

Malta - enska - Medicines Authority

viatris hellas ltd 253-255, mesogion avenue, 154 51 neo psychiko, athens,, greece - eletriptan hydrobromide - film-coated tablet - eletriptan hydrobromide 20 mg - analgesics